scholarly journals Correction: The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207736
Author(s):  
Ho Ra ◽  
Lina D. Song ◽  
Jin A. Choi ◽  
Donghyun Jee
Keyword(s):  
Cost Effectiveness ◽  
South Korea ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Systematic Screening ◽  
Age Related ◽  
The Cost

scholarly journals Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhuang Cui ◽  
Wei Zhou ◽  
Qinxue Chang ◽  
Tiantian Zhang ◽  
Hui Wang ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Macular Degeneration ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Transition Probabilities ◽  
Age Related Macular Degeneration ◽  
Chain Model ◽  
Pathological Myopia ◽  
Age Related ◽  
The Cost

Background: With the advent of aging society of China, fundus diseases related to pathological neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), and pathological myopia (PM), have become an increasingly serious medical and health problems. As effective drugs of the treatment, conbercept and ranibizumab have been commonly used and covered by the national basic medical insurance in China. However, the pharmacoeconomic evaluation of conbercept vs. ranibizumab for DME and PM remains lacking. This study would assess the cost-effectiveness of conbercept and ranibizumab for the treatment of AMD, DME, and PM from the perspective of Chinese payers.Methods: A Markov chain model was constructed based on the visual conditions of the patient indicated by the number of letters in best corrected visual acuity (BCVA). We conducted models based on real-world scenario to calculate the cost per the quality-adjusted life-year (QALY) gained. A 1-year cycle length and a 10-year simulation treatment were applied and the number of injections of conbercept and ranibizumab was assumed to the average number within 10 years. Transition probabilities, costs, utility data, and other parameters were obtained from literature searches. A 3.5% discounting rate was applied for both the costs and utilities.Results: The incremental cost-effectiveness ratios (ICERs) were more favorable for conbercept than ranibizumab in treatment of AMD, DME, and PM, with associated ICER of 66,669 renminbi (RMB), −258,813 RMB, and −373,185 RMB per QALY gained. Compared with ranibizumab, the incremental effectiveness of conbercept in treatment of AMD, DME, and PM was −0.665 QALYs, 0.215 QALYs, and 0.029 QALYs, respectively. The sensitivity analysis showed the same findings, although the ICER is sensitive to the costs of this program.Conclusion: Under the current Chinese healthcare setting, conbercept is suitable and cost-effective in treatment of AMD, DME, and PM compared with ranibizumab.

scholarly journals Bevacizumab vs. Ranibizumab in Preserving or Improving Vision in Patients with Wet, Age-Related Macular Degeneration: A cost-effectiveness Review

2012 ◽  
Vol 4 ◽  
pp. CMT.S7439
Author(s):  
Chukwuemeka C. Nwanze ◽  
Abumere Akinwale ◽  
Ron A. Adelman
Keyword(s):  
Cost Effectiveness ◽  
Adverse Events ◽  
Macular Degeneration ◽  
Treatment Protocol ◽  
Cost Effective ◽  
Treatment Costs ◽  
Age Related Macular Degeneration ◽  
Insurance Company ◽  
Age Related ◽  
The Cost

Objective To evaluate the cost-effectiveness of monthly and as-needed dosing protocols using ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (AMD), when the treatment costs of severe ocular and systemic adverse events are considered. Methods A Markov model was developed to assess the cost effectiveness of each of the following protocols: monthly ranibizumab, monthly bevacizumab, as-needed ranibizumab and as-needed bevacizumab. Direct costs and utilities were assessed from the perspective of a third-party payer or an insurance company. Cost effectiveness was evaluated in 2011 US dollars per quality-adjusted life year (QALY). Results Considering the treatment costs of severe medical and ocular adverse events, the cost effectiveness of each protocol is as follows: monthly ranibizumab $63,333/QALY, ranibizumab as needed $18,571/QALY, bevacizumab monthly $2,676/QALY and bevacizumab as needed $3,333/QALY Sensitivity analysis of the treatment costs of medical and ocular adverse events demonstrated minimal impact on relative cost-effectiveness. Conclusion At current prices, monthly bevacizumab is the most cost-effective anti-VEGF AMD treatment protocol. Ranibizumab is as cost effective as bevacizumab at a maximum price of $158 per dose.

Sign in / Sign up

Export Citation Format

Share Document